To Top

Search By Topic

Contract Development and Manufacturing (CDMO)

153 Articles available
Biopharmaceutical Industry

Avara on the Road to BIO: Taking Direction From Industry Veterans

Bill Pasek, Executive Vice President & Chief Commercial Officer, Avara Pharmaceutical Services
View more about Avara Pharmaceutical Services on the Road to BIO.

PTV-M06-17-CL-008
Process Analytical Technology

Making Real-Time Process Analytical Technology In Biomanufacturing A Reality

PAP-Q2-17-IL-001
CDMO

Supporting the Tech Transfer Continuum for Cell & Gene Therapies

PAP-Q2-17-CL-003
Biologics

Propagating a Full Spectrum of Services for ADC Development and Manufacture

PAP-Q2-17-CL-007
API

Optimizing API Production as a True Manufacturing Partner

PAP-Q2-17-CL-009
API

Small Molecule Injectable Manufacturing: Challenges and Complexities

PAP-Q2-17-CL-013
CDMO

Building a One-Stop Shop CDMO for Biopharmaceuticals

PAP-Q2-17-CL-012
CDMO

Orphan Xermelo Begins Commercial Manufacture

PAO-M05-17-NI-018
Clinical Trial

Expanding Into Clinical Trials

Jeff Schwegman, CEO, AB Biotechnologies 

PTV-M03-17-IN-012
CDMO

Latest Developments in Cellular and Gene Therapies

MCP-M03-17-NI-001
CDMO

Upcoming: Women in Leadership Forum

PAO-M04-17-NI-023
CDMO

Bioprocessing Capacity is in High Demand

PAO-M04-17-NI-022
CDMO

Cobra Biologics Invests in Gene Therapy

PAO-M04-17-NI-020
CDMO

Meeting Customer Needs

James E. Gregory, President and CEO, UPM Pharmaceuticals

PTV-M01-17-NS-014
CDMO

Famar Expands Into North America

PAO-M04-17-NI-019
CDMO

Topical Drug Formulations – Strong Growth Based on New Understandings: Q&A with BASF Pharma Solutions

PAO-M04-17-NI-014
CDMO

Rentschler Sharpens its Competitive Edge

PAO-M04-17-NI-017
CDMO

Grand River Has Come a Long Way

Tom Ross, President and CEO, Grand River

PTV-M11-16-AP-026
CDMO

Catalent Completes Controlled-Temperature Capacity

PAO-M04-17-NI-012
CDMO

Benefitting from Embedded Quality for End-to-End Success

Gwenael Servant, Managing Director, Servier CDMO

PTV-M01-17-NS-010
CDMO

A Growing CDMO

Bill Pasek, Executive Vice President & Chief Commercial Officer, Avara Pharmaceutical Services

PTV-M01-17-NS-009
CDMO

Oral Solid Dose Train-the-Trainer for Production Personnel

Michael Tousey, CEO and Technical Director, Techceuticals

PTV-M01-17-NS-007
CDMO

Cleaning and Validation

Michael Moussourakis, Senior Manager, Technical Marketing and Commercial Development, Alconox, Inc.

PTV-M01-17-NS-004
CDMO

The Capsule Manufacturing Market

Ajit Singh, Chairman, ACG Worldwide

PTV-M11-16-AP-002
CDMO

Innovation is Key

Marco Gil, General Manager, Hovione

PTV-M11-16-AP-003
CDMO

Choosing the Right Pathway

Ken Phelps, President & CEO, Camargo

PTV-M11-16-AP-007
CDMO

Growing Through Consolidation

Derek Hennecke, Xcelience - a division of Capsugel, CEO and President

PTV-M11-16-AP-008
CDMO

Servier Offers Quality Service

Gwenael Servant, Managing Director, Servier CDMO

PTV-M11-16-AP-012
API

Filling a Market Need

Abby Thompson, Global Marketing Communications Manager, Corden Pharma

PTV-M11-16-AP-016
CDMO

Patheon Leads in New Drug Approvals

PAO-M04-17-NI-011
CDMO

Sartorius Acquires Umetrics

PAO-M04-17-NI-010
CDMO

Relay Therapeutics Tags Sanjiv Patel for CEO Position

PAO-M04-17-NI-006
CDMO

Vetter’s Roth Appointed to Fraunhofer Advisory Board

PAO-M04-17-NI-004
CDMO

Avista Pharma Solutions Completes $4 Million Expansion

PAO-M04-17-NI-002
CDMO

Understanding Solid State Properties for Formulation Success

PAO-M04-17-NI-001
CDMO

Eli Lilly to Spend $850 Million on U.S. Manufacturing

PAO-M03-17-NI-018
CDMO

Cracking Soil’s Microbiome: Biopesticides and Plant Biostimulants

SCP-M03-17-NI-001
CDMO

Siegfried Sees Rise in Sales after Acquisitions

PAO-M03-17-NI-017
CDMO

Pfizer CentreOne Expands on Two Fronts

PAO-M03-17-NI-015
CDMO

Charles River and Chiesi to Extend Six-year Partnership

PAO-M03-17-NI-012
CDMO

Fine Industries Sold to Lianhetech

PAO-M03-17-NI-009
CDMO

Sanofi, Lonza Invest in Large-Scale Biologics Partnership

PAO-M03-17-NI-007
CDMO

The Data Generation

PAP-Q1-17-IN-001
API

Continuous Manufacturing: To Be Continued…

PAP-Q1-17-VP-001
CDMO

Industry Benchmark: Introduction

PAP-Q1-17-FA-001
API

Changes in the Wind for the CDMO Market

PAP-Q1-17-FA-002
CDMO

Investors May Look Smaller

PAP-Q1-17-FA-008
CDMO

2017 Top 5 Industry Leader

PAP-Q1-17-IL-001
CDMO

Operational Excellence in Outsourced Fill-Finish Services

PAP-Q1-17-IC-001
API

Expanding the Commercial Options for Preparation of Amorphous Solid Dispersions

PAP-Q1-17-CL-006
CDMO

Q: What Challenges are Associated with Implementing Cloud Computing within CROs/CDMOs?

PAP-Q1-17-RT-004
CDMO

Flexible Partnership, Inflexible Quality

PAP-Q1-17-CL-016
CDMO

Pharma’s Reputation Gap: Consumer Business Innovation

PAP-Q1-17-CL-009
CDMO

Facilitating Tech Transfer for Parenteral Products

PAP-Q1-17-CL-010
API

Particle Engineering for Improved Bioavailability in Oral Solid Dose Medications

PAP-Q1-17-CL-014
API

Next-Generation OSD Manufacturing Strategy

PAP-Q1-17-CL-015
API

Innovation and Partnership Through Experience and Acquisition

PAP-Q1-17-CL-013
API

Supporting the Pharma Industry Small Business Growth Engine

PAP-Q1-17-CL-017
CDMO

Enhancing Responsiveness with Embedded Flexibility

PAP-Q1-17-CL-008
CDMO

Keys to Cultural Integration

PAP-Q1-17-QA-001
API

Experience and Expertise Facilitate Controlled Substance Manufacturing

PAP-Q1-17-CL-004
API

Achieving Security of Supply with Effective Particle Engineering

PAP-Q1-17-CL-002
CDMO

Nice Symposium Oral Solid Dose Thank You to Our 2017 Sponsors

PAP-Q1-17-NS-001
API

Lifecycle Management Strategies Can Uncover Hidden Value

PMP-M03-17-NI-001
CDMO

Serialization and Standardization: The Challenge

PAO-M02-17-NI-002
CDMO

Human Factors Engineering and the Variability of the Human Condition

APR-M02-17-NI-001
CDMO

Lonza Rings the Changes with Capsugel Buy

PAO-M12-16-NI-004
CDMO

The Rise of Biosimilars

PMO-M12-NI-16-001
CDMO

Raw Material Supply: Many Issues to Manage

POP-M10-16-NI-001
CDMO

Beginning Your Digital Transformation

CPP-M11-16-NI-001
CDMO

Incorporating QbD into Lyophilization Manufacturing

CPO-M09-16-NI-001
CDMO

2016 CDMO Industry Leaders

PAP-Q02-16-IL-001
CDMO

Investment in Biopharma Facilities Continues

PMO-M11-16-NI-001
CDMO

Cambrex and Axyntis Moving Towards CDMOs

PAO-M10-16-NI-002
CDMO

A Foundation of Innovation

PAP-Q04-16-IN-001
CDMO

Q: What New Technology Introduced Within the Last Year Have You Found to Have the Most Impact on Your Business?

PAP-Q04-16-RT-001
API

A New Industry Think Tank Forum for Leaders of Outsourced Services and Customers

PAP-Q04-16-NS-001
CDMO

This Just In

PAP-Q04-16-JI-001
API

Finding The Ideal Partner for Your Next Biotherapeutic

PAP-Q04-16-CL-013
API

Designing Effective Drug Formulations: Keys to Successful Proof of Concept Services

PAP-Q04-16-CL-004
CDMO

Supply Chain Management and the Importance of Security of Supply

PAP-Q04-16-CL-002
API

Cultivating a Proactive Quality Culture

PAP-Q04-16-CL-008
API

Dry-Powder Inhalation Formulation: Balancing Performance and Manufacturability

PAP-Q04-16-CL-006
API

Capsugel’s Transformation: Q&A with Guido Driesen

PAP-Q04-16-QA-001
CDMO

Pharmaceutical Packaging: Differentiation Equates to Brand Loyalty

PAP-Q04-16-VP-001
CDMO

Q: What is Your Perception of the State of Serialization in Your Sector of the Pharma Industry?

PAP-Q04-16-RT-003
CDMO

Nice Insight Launches 2017 Study Season

PAP-Q04-16-NI-001
API

New Strategies Required to Meet Changing Needs in the Analytical Services Market

PAP-Q04-16-CL-010
CDMO

Equipment Redeployment’s Strategic Role

PAP-Q04-16-CL-005
CDMO

Achieving Successful Treatment Outcomes Through the Delivery of Manufacturing Services

PAP-Q04-16-CL-012
CDMO

Transforming the Pharmaceutical Industry Pipeline with In Silico Approaches

PAP-Q04-16-CL-011
CDMO

Seeking Quality Deals: Consolidation and Acquisition

PAP-Q04-16-VP-002
CDMO

Rx-360: An Industry Group Like No Other

PAP-Q04-16-CL-007
API

Meeting Unmet Patient Needs with Small-Volume APIs

PAP-Q04-16-CL-003
API

Targeted, Highly Potent Therapies: Big Growth Driver for the CDMO Market is Here...

SCP-M09-16-NI-001
CDMO

Pharma’s Role in Pediatric Medication Adherence

PMP-M08-16-NI-001
CDMO

Harnessing CDMO Expertise for Fill-Finish and Inspection of Sterile Pharmaceuticals

PAP-Q03-16-CL-015
CDMO

CDMOs Crucial for Bringing Promising Next-Generation Therapies to Market

PAP-Q03-16-CL-013
API

Process Performance Qualification Prep: a Strategic Approach Leads to Success

PAP-Q03-16-CL-008
CDMO

Nice Insight Overview: The Key to Pharma’s Next Generation Success

PAP-Q03-16-NO-001
CDMO

Collaboration is the Name of the Game

PAP-Q03-16-IN-001
CDMO

Delivering on Unfulfilled Promises – Building a CDMO

PAP-Q03-16-CL-006
CDMO

Patient-Centric Drug Development: Designing Medicines to Succeed

PAP-Q03-16-CL-004
CDMO

Analytical Method Development: Key to Process Development

PAP-Q03-16-CL-002
CDMO

Pharma’s Renaissance Continues

PAP-Q03-16-ED-001
API

Joint Venture Contract Services – A CDMO’s Approach to Being a True Partner

PAP-Q03-16-CL-016
CDMO

Evolving Strategic Partnership Models

PAP-Q03-16-CL-007
CDMO

Sustainable Strategies for Contract Development and Manfacturing Service Growth

PAP-Q03-16-NC-001
API

Embracing Formulation Expertise to Extend Exclusivity & Improve the Patient Experience

PAP-Q03-16-CL-005
API

Accelerating Approval and Reducing Costs of Spray Dried Drugs Through Development by Design (DbD)

PAP-Q03-16-CL-011
CDMO

Effective Quality Assurance Capabilities Essential for CDMO/CRO Success

MCP-M07-16-NI-001
CDMO

Sponsor Company Size Influences Contract Service Provision

POP-M05-16-NI-001
CDMO

Increasing the Chances of Finding the Best Possible CRO/CMO Fit

MCP-M05-16-NI-001
API

Biocatalysis Versus Chemocatalysis

MCP-M04-16-NI-001
CDMO

Research Database Recommendations

PAP-Q02-16-NI-001
API

Quality Culture Wins Over Compliance

PAP-Q02-16-CL-001
CDMO

Process Safety Evaluations Crucial to Successful CDMO Operations

PAP-Q02-16-CL-009
API

Establishing Specialized CDMO Capabilities for the Production of Advanced Therapies

PAP-Q02-16-CL-007
CDMO

Enabling Right-First-Time Tech Transfer with Effective Scale-Down Modeling

PAP-Q02-16-CL-002
CDMO

Biopharma’s Ascendent Supply Chain Reveals its Present Potential & Future Promise

PAP-Q02-16-FA-001
CDMO

From Qualified to Ideal: The Importance of Partnership

PAP-Q02-16-VP-001
CDMO

Single-Use Equipment Proving Useful Managing Biomanufacturing Costs

PAP-Q02-16-NI-002
CDMO

Rigorous Integration in a Scalable Development and Manufacturing Enterprise to Support Continued Growth of Biopharmaceuticals

PAP-Q02-16-CL-011
CDMO

Achieving Large-Scale Cell and Gene Therapy Manufacturing

PAP-Q02-16-CL-010
API

Expect Pharmaceutical Contract Manufacturing to Continue Apace in 2016

POP-M03-16-NI-001
CDMO

Nice Insight Outsourcing Trends in 2016

APR-M03-16-NI-001
CDMO

The Importance of Convenient Dosing Formulations for Elderly Patients

PAP-Q1-16-CL-008
CDMO

Putting the “D” in CDMO with Advanced Process Development

PAP-Q1-16-CL-002
API

Patient Safety and Parenteral Delivery Systems

PAP-Q1-16-CL-010
CDMO

Customer Experience: Key to Growth in the Outsourced Services Industry

PAP-Q1-16-IC-001
CDMO

Advancing Biologics Development and Manufacturing

PAP-Q1-16-CL-011
API

Strong CMO/CDMO Market Outlook for 2016, but Beware Moderating Factors

PAP-Q1-16-FA-001
API

Good Laboratory Practices Lead to Good Manufacturing in CDMOs

PAP-Q1-16-CL-009
API

Single-Use Now Key Technology in Biopharmaceutical Manufacturing

POP-M01-16-NI-001
API

Formulation Challenges Drive Interest in CDMOS

MCP-M01-16-NI-001
CDMO

Will Biosimilars Make a Difference for the CMO/CDMO Market?

POP-M11-15-NI-001
API

Bolstering Capabilities for Parenteral Drug Development and Manufacturing

PAP-Q4-15-CL-005
CDMO

A Look At 2015 Outsourcing Trends And What To Expect In 2016

LSL-M10-15-NI-001
CDMO

Environmental Monitoring Benefits from Technological Innovation

APR-M07-15-NI-001
CDMO

Four Keys to Successful Biopharmaceutical Outsourcing: Technical Expertise, Quality, Reliability and Timeliness

PAP-APR-S01-CL-001
CDMO

What Does 2015 Hold For The Indian CMO Industry?

LSL-M03-15-NI-003
CDMO

The CDMO Model And Outsourcing Development

LSL-M02-15-NI-001
CDMO

New Technologies In Fill-Finish May Bring Brand Loyalty Along with Improved Patient Safety

LSL-M04-14-NI-001
CDMO

Increased Demand for Vaccines will Continue to Benefit CMOs

CIO-M04-14-NI-001
CDMO

Process Optimization: Innovation's Role

PPO-M04-12-NI-001
CDMO

Customer Drivers Influencing Supplier Differentiation

PTO-M08-11-NI-001
//Fix for text overflow in cards